Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients

Table 1

Patient’s characteristics before initiation of treatment with TNFα blockers.

	RA, (42.9%)	SpA, (57.1%)
Median disease duration before initiation of TNFα blocker, years, median (IQR)	8.0 (4.0–20.0)	6.0 (2.0–11.75)
CRP, mg/L, mean ± SD	31.71 ± 20.86	35.87 ± 23.30
ESR, mm/h, mean ± SD	42.1 ± 25.17	44.6 ± 26.61
DAS-28, mean ± SD	5.76 ± 1.35	Na
HAQ, mean ± SD	1.37 ± 0.78	1.3 ± 0.63
ASDAS, mean ± SD	Na	15.41 ± 6.13^*
BASDAI, cm, mean ± SD	Na	5.5 ± 2.78^*
BASFI, cm, mean ± SD	Na	4.78 ± 2.62^*
MASES index, mean ± SD	Na	4 ± 2
Patient’s global VAS, mm, mean ± SD	64.19 ± 21.45	67.66 ± 20.5
Patient’s pain VAS, mm, mean ± SD	63.43 ± 22.29	68.97 ± 20.33
Doctor’s global VAS, mm, mean ± SD	57.61 ± 18.16	58.32 ± 11.36
Swollen joints, mean ± SD	17 ± 8	10 ± 8
28 swollen joints, mean ± SD	10 ± 7	Na
Tender joints, mean ± SD	22 ± 15	20 ± 14
28 tender joints, mean ± SD	10 ± 9	Na

Notes: data presented mean ± standard deviation (SD) or median and interquartile range (IQR); ^*axial forms of SpA.
Abbreviations: RA: rheumatoid arthritis, SpA: spondyloarthritis, CRP: C reactive protein, ESR: erythrocyte sedimentation rate, DAS-28: disease activity score in 28 joints, HAQ: Health Assessment Questionnaire, ASDAS: ankylosing spondylitis disease activity score, BASDAI: bath ankylosing spondylitis disease activity score, BASFI: bath ankylosing spondylitis functional index, MASES: Maastricht ankylosing spondylitis entesitis score, VAS: visual analogue scale, and Na: not applicable.